Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Opcium
- Development stage
- Unknown
- Lead developer
- Opsiscare Lifesciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Opcium is an oral dietary supplement marketed by Opsiscare Lifesciences. It is a combination formulation containing calcium citrate, magnesium hydroxide, cholecalciferol (vitamin D3), and zinc. This combination is designed to support bone health, prevent or treat calcium and vitamin D deficiencies, and support immune and muscle function. Calcium citrate provides highly bioavailable calcium for bone mineralization, while cholecalciferol enhances intestinal calcium absorption. Magnesium and zinc serve as essential cofactors in bone metabolism, enzymatic reactions, and cellular functions.
- Brand names
- OpciumOpcium DS
- Other names
- calcium citrate + magnesium hydroxide + cholecalciferol + zinc
02
Targets
Beyond the preview
Go deeper on Opcium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Opcium.